{"analyses":[{"ciLowerLimit":"-12.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-3.6","estimateComment":"Rate difference is the zanubrutinib rate minus the ibrutinib rate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","paramType":"Rate Difference","paramValue":"-8.0","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"8.3","value":"5.2"},{"groupId":"OG001","lowerLimit":"9.8","upperLimit":"17.5","value":"13.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"324"}],"units":"Participants"}],"description":"Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either \"atrial fibrillation\" or \"atrial flutter\".","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG000","title":"Zanubrutinib"},{"description":"Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG001","title":"Ibrutinib"}],"paramType":"NUMBER","populationDescription":"The Safety Analysis Set includes all participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).","title":"Percentage of Participants With Atrial Fibrillation or Atrial Flutter","type":"SECONDARY","unitOfMeasure":"percentage of participants"}